Delivery Order SPE2DR25D2014-SPE2DR26FZ60L
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of TYPHIM VI 25 MCG/0.5 ML syringes valued at $3,080.32. This is a firm fixed-price delivery order with an ultimate completion date of September 18, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's competitive...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of TYPHIM VI 25 MCG/0.5 ML syringes valued at $6,278.09. This is a firm fixed price delivery order with an ultimate completion date of August 22, 2025, to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting open competition among eligible vendors. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of TYPHIM VI 25 MCG/0.5 ML syringes valued at $1,379.80. This is a firm fixed-price delivery order with an ultimate completion date of August 4, 2025, to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract was awarded through open competition with no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency awarded a $6,679 firm fixed price delivery order to AmerisourceBergen Drug Corp on October 20, 2025, for TYPHIM VI 25 MCG/0.5 ML syringes. The contract, which is a child of AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX valued at $999,999,999 through December 2026), represents a competitively awarded, non-set-aside procurement with an ultimate completion date of October 21, 2025. Performance will take place at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of TYPHIM VI 25 MCG/0.5 ML syringes valued at $10.75K with a completion date of August 4, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a small-value transaction within AmerisourceBergen's broader pharmaceutical distribution portfolio. The place of performance is located in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 21, 2025, for the supply of TYPHIM VI 25 MCG/0.5 ML syringes valued at $17,854.65, with completion scheduled for October 22, 2025. This non-set-aside, competitively awarded contract employs firm fixed pricing and represents a child order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The place of performance is the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,449.50 to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of TYPHIM VI 25 MCG/0.5 ML syringes. This competitive, firm fixed-price delivery order will be fulfilled at the contractor's location in Conshohocken, Pennsylvania, with an ultimate completion date of September 5, 2025. The award represents a small-value transaction typical of the company's extensive portfolio of pharmaceutical and medical supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of TYPHIM VI 25 MCG/0.5 ML syringes valued at $5,174.25. This is a firm fixed-price delivery order with an ultimate completion date of April 25, 2025, to be performed at the contractor's location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to meet federal...
- The Defense Logistics Agency awarded a delivery order valued at $11,684.46 to AmerisourceBergen Drug Corp for TYPHIM VI 25 MCG/0.5 ML syringes on November 4, 2025, with completion scheduled for November 5, 2025. This firm fixed-price contract, which involves no set-aside designation, represents a competitive award supporting federal medical procurement needs. The product will be delivered to the company's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $3,449.00 to AmerisourceBergen Drug Corp on October 29, 2025, for the supply of TYPHIM VI 25 MCG/0.5 ML syringes. This competitively awarded, firm fixed-price delivery order will be completed by October 30, 2025, with performance taking place at the contractor's Corporate Office location in Conshohocken, Pennsylvania. No set-aside designation was applied to this contract action. This delivery order falls under AmerisourceBergen Drug...
- SPE2DR25D2014Indefinite Delivery Contract
- SPE2DR25D2014-SPE2DR26FZ60LDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of TYPHIM VI 25 MCG/0.5 ML syringes, with a ceiling value of $6,696.44. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, reflecting AmerisourceBergen's capability to compete openly in federal pharmaceutical procurement. The contract is set to be completed by November 4, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a single transaction under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen supplies a comprehensive range of pharmaceutical products and medical supplies to support military healthcare systems and other government agencies. The company's extensive contract portfolio with DLA demonstrates its established role in the federal medical supply chain, providing everything from specialty medications to vaccines and medical devices across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.7k | 11/3/25 |